CN104203267A - 用于治疗流感和副流感患者的方法、化合物和组合物 - Google Patents

用于治疗流感和副流感患者的方法、化合物和组合物 Download PDF

Info

Publication number
CN104203267A
CN104203267A CN201380009763.6A CN201380009763A CN104203267A CN 104203267 A CN104203267 A CN 104203267A CN 201380009763 A CN201380009763 A CN 201380009763A CN 104203267 A CN104203267 A CN 104203267A
Authority
CN
China
Prior art keywords
patient
das181
virus
infection
sialidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380009763.6A
Other languages
English (en)
Chinese (zh)
Inventor
朗·莫斯
李铁军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Priority to CN201811368987.7A priority Critical patent/CN109529026A/zh
Publication of CN104203267A publication Critical patent/CN104203267A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380009763.6A 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物 Pending CN104203267A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811368987.7A CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811368987.7A Division CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Publications (1)

Publication Number Publication Date
CN104203267A true CN104203267A (zh) 2014-12-10

Family

ID=48984833

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380009763.6A Pending CN104203267A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物
CN201811368987.7A Pending CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811368987.7A Pending CN109529026A (zh) 2012-02-17 2013-02-19 用于治疗流感和副流感患者的方法、化合物和组合物

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN104203267A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
KR20170081213A (ko) 2014-11-06 2017-07-11 다나-파버 캔서 인스티튜트 인크. Ezh2 억제제 및 그의 용도
CA2966336A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
EP4065139A1 (en) * 2019-11-25 2022-10-05 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081624A1 (en) * 2002-09-06 2004-04-29 Chrysalis Technologies Incorporated Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
US20090142327A1 (en) * 2002-11-22 2009-06-04 Fang Fang Novel Class of Therapeutic Protein Based Molecules
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
KR20150001844A (ko) * 2006-01-24 2015-01-06 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081624A1 (en) * 2002-09-06 2004-04-29 Chrysalis Technologies Incorporated Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
US20090142327A1 (en) * 2002-11-22 2009-06-04 Fang Fang Novel Class of Therapeutic Protein Based Molecules
US20110171132A1 (en) * 2009-11-06 2011-07-14 Nexbio, Inc. Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract
CN102711807A (zh) * 2009-11-06 2012-10-03 耐百生物制药有限公司 用于在呼吸道中进行治疗和预防的方法、化合物和组合物

Also Published As

Publication number Publication date
ES2970401T3 (es) 2024-05-28
EP2841092C0 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
AU2019226190A1 (en) 2019-09-26
IL273194B2 (en) 2023-02-01
IL234116B (en) 2020-03-31
IL273194B (en) 2022-10-01
EP2841092A1 (en) 2015-03-04
EP2841092A4 (en) 2015-09-16
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
US20170151315A1 (en) 2017-06-01
CN109529026A (zh) 2019-03-29
CA2864746A1 (en) 2013-08-22
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194A (en) 2020-04-30
JP2015508780A (ja) 2015-03-23
AU2017258955A1 (en) 2017-12-14
AU2013221230A1 (en) 2014-10-02
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
US20150132274A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
WO2011057081A1 (en) Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
CN112546046B (zh) 盐酸阿比朵尔在制备治疗肺纤维化疾病药物中的应用
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
WO2020109621A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
CN108926707A (zh) Pf4的抗rsv应用
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20260007656A1 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, pulmonary arterial hypertension, adn respiratory syncytial virus
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
WO2024096743A1 (en) Sars-cov-2 binding antibody
US20250241978A1 (en) Peptide for prevention or treatment of covid-19
EP4507720A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210